All blog articles
Clinical Corner

Benefits of using CGM with GLP-1 drugs for diabetes treatment


Oct. 18, 2024 5 min read

The content in this article should not be taken as medical advice. Please consult your healthcare provider regarding your individual health needs.

GLP-1 medications are one of the hottest topics in diabetes and have shown to be very effective.1 In this article we will take a look at the GLP-1 class of medication, and highlight a few of the big reasons why Dexcom CGM can be complementary for people with diabetes (PWD) who are starting, currently taking, or adjusting dosage of a GLP-1.


How do GLP-1 drugs work?

GLP-1s work in multiple ways in the body including slowing down the digestion of food and release of glucose into the bloodstream, increasing insulin secretion in response to a meal, and regulating appetite control signals in the brain. Together, these effects have shown to help improve glucose management.


Ask your doctor to learn more about GLP-1 medications and about getting started on a Dexcom CGM. We can also help you get started with a free benefits check for your Dexcom CGM. Click the button below to send us some basic information.
  • Get started

*Data comes from a 2018-2023 US Data Base of payor claims as a retrospective, observational analysis. CGM (N=101) + GLP-1 vs GLP-1 only (N=5840). GLP-1 only group (control) showed a 0.99% A1C reduction.
**Dr. Timothy Gilbert is a paid spokesperson for Dexcom
1 Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(4):251-260. doi:10.1016/S2213-8587(17)30013-X. 2 Tsapas A, Avgerinos I, Karagiannis T, et al. Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis. Ann Intern Med. 2020;173(4):278-286. doi:10.7326/M20-0864. 3 Ehrhardt N, Al Zaghal E. Continuous Glucose Monitoring As a Behavior Modification Tool. Clin Diabetes. 2020;38(2):126-131. doi:10.2337/ cd19-0037. 4 Dexcom, Data on File, 2023. 5 Polonsky WH, Henry RR. Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. Patient Prefer Adherence. 2016;10:1299-1307. Published 2016 Jul 22. doi:10.2147/PPA.S106821
BRIEF SAFETY STATEMENT: Failure to use the Dexcom Continuous Glucose Monitoring System and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety- information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the Dexcom CGM do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency.
Dexcom, Dexcom Clarity, Dexcom Follow, Dexcom One, Dexcom Share, and any related logos and design marks are either registered trademarks or trademarks of Dexcom, Inc. in the United States and/or other countries.

Related articles

View all
Privacy PolicyTerms of Use

LBL-1001419 Rev008

MAT-2259

© Dexcom, Inc. All rights reserved.

US flag

US